Patients with end‐stage renal disease (ESRD) develop hemostatic disorders mainly in the
form of bleeding diatheses. Hemorrhage can occur at cutaneous, mucosal, or serosal sites …

Uremic bleeding syndrome is a recognized consequence of renal failure and can result in
clinically significant sequelae. Although the pathophysiology of the condition has yet to be …

The demand for platelets in England was stable at around 220,000 adult therapeutic doses
(ATD) per year until 2007/8 at which point demand has increased year on year to 275,000 …

Objective: To develop evidence-based recommendations for safe, effective, and appropriate
treatment of secondary (SHPT) and tertiary (THPT) renal hyperparathyroidism. Background …

A recent study in dogs suggested that erythropoietin (EPO) not only promotes the synthesis
of increased numbers of reticulated platelets but that these newly produced platelets are …

Background Despite the widespread use of erythropoietin-stimulating agents (ESAs) to treat
anemia in patients undergoing hemodialysis, the relative mortality risks associated with use …

With the rising prevalence of kidney disease, clinicians are increasingly faced with concerns
about potential thrombotic and bleeding complications. Thrombotic risk, both arterial and …

Chronic kidney disease (CKD) is an independent risk factor for the development of
cerebrovascular disease, particularly small vessel disease which can manifest in a variety of …

Two hundred patients who were scheduled for a major elective orthopaedic operation were
enrolled in a prospective study and were randomly assigned to one of three treatment …

Although renal failure has classically been associated with a bleeding tendency, thrombotic
events are common among patients with end‐stage renal disease (ESRD). A variety of …